ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. The Trump administration is planning to use artificial ...

The two companies agreed to cooperate in the development of all-solid-state battery materials. In sample testing of materials from multiple suppliers, POSCO Future M demonstrated good rate capability.

For as long as vow exchanges have existed, there have been those who’ve struggled to write them. The practice asks people to condense their love, appreciation, and commitment to their partner into a ...

Forbes contributors publish independent expert analyses and insights. I’m a clear communications expert and Plain Language advocate. This voice experience is generated by AI. Learn more. This voice ...

A growing number of special education teachers say they use artificial intelligence platforms to draft all or part of students’ individualized education programs, even as many districts lack policies ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

People are using AI to write sensitive messages to loved ones. Detecting AI-generated text is becoming more difficult as chatbots evolve. Some tech leaders have promoted this use of AI in their ...

We all lose our gadgets every once in a while. Finding them isn’t always straightforward, especially if they have been stolen or left behind in a different place. Likewise, if it’s nestled between the ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Community driven content discussing all aspects of software development from DevOps to design patterns. All you need to do is open an online editor and code away! Which is exactly what we’re going to ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...